Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors

BACKGROUND: Overexpression of Galectin-3 (Gal-3), a β-galactoside binding protein, has been noted in many tumour types but its functional significance and clinical utility in gastric adenocarcinoma (GAC) are not well known. METHODS: We studied 184 GAC patients characterised by histologic grade, sub-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Cancer
Hauptverfasser: Ajani, Jaffer A, Estrella, Jeannelyn S, Chen, Qiongrong, Correa, Arlene M, Ma, Lang, Scott, Ailing W, Jin, Jiankang, Liu, Bin, Xie, Min, Sudo, Kazuki, Shiozaki, Hironori, Badgwell, Brian, Weston, Brian, Lee, Jeffrey H, Bhutani, Manoop S, Onodera, Hisashi, Suzuki, Koyu, Suzuki, Akihiro, Ding, Sheng, Hofstetter, Wayne L, Johnson, Randy L, Bresalier, Robert S, Song, Shumei
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2018
Schlagworte:
Translational Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765229/
https://ncbi.nlm.nih.gov/pubmed/29136404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.388
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge